ICYMI, this week we had stories about FDA approvals, biologics vs biosimilars, CTCL treatment, atopic dermatitis in patients with skin of color, and more.
Click here to answer this week's poll.
Click to see a preview of what to expect this week.
Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of ustekinumab as a new treatment option for patients aged 6 years or older with active psoriatic arthritis.
Roy M. Fleischmann, MD and Joel M. Gelfand, MD, MSCE, FAAD define the terms biologic and biosimilars and discuss how they are developed.
Drs Roy M. Fleischmann and Joel M. Gelfand discuss differences between biosimilars and reference products.
Soligenix announces positive phase 3 results from FLASH study for the use of synthetic hypericin to reduce cutaneous T-cell lymphoma lesions.
Harnessing digital marketing tools can help your medical practice grow.
Drs Lamb, Noor, and Bhatia discuss their approach to selecting treatment in light of recent AD approvals.
Drs Noor and Lamb discuss mechanisms of action of biologics and JAK inhibitors and the importance of patient communication while selecting AD treatments.
In this week’s Pointers with Dr Portela, the 208SkinDoc travels to the La Roche-Posay Thermal Treatment Center.
Allergan Aesthetics announced the US Food and Drug Administration has approved the hyaluronic acid filler for jawline definition improvement.
An interview with Shino Bay Aguilera, DO, on the current state of the aesthetic industry.
The sweeping legislation contains tax code reform, health care provisions and climate change action. What does it mean for physicians?